1 / 17

Varenicline for smoking cessation

Varenicline for smoking cessation. Robert West University College London Logroño, October 2006 www.rjwest.co.uk. Outline. Mechanism of action Clinical findings Comparison with other medications. Mechanism of action. It is proposed that:

lillyd
Download Presentation

Varenicline for smoking cessation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Varenicline for smoking cessation Robert West University College London Logroño, October 2006 www.rjwest.co.uk

  2. Outline • Mechanism of action • Clinical findings • Comparison with other medications

  3. Mechanism of action • It is proposed that: • Chronic nicotine ingestion from cigarettes sets up an acquired drive resulting from chronically reduced activity in the mesolimbic dopamine pathway experienced as a ‘need’ to smoke analogous to need for food etc. • Nicotine stimulates activity in the mesolimbic dopamine pathway, relieving the drive state and also providing positive reward • Varenicline attaches to the nicotine receptors concerned and activates them to a limited degree, reducing the drive state and blocking nicotine from attaching to the receptors

  4. Smoking Impulse to smoke Cues/triggers Anticipated enjoyment Desire to smoke Need to smoke Nicotine ‘hunger’ Unpleasant mood and physical symptoms Anticipated benefit Reminders Positive evaluations of smoking Smoker ‘identity’ Beliefs about benefits of smoking Motivation to smoke www.primetheory.com

  5. Action on the nicotinic receptor • Varenicline is a ‘partial agonist’ binding with high affinity to the α4β2 nicotinic acetylcholine receptor believed to be important in the development and maintenance of nicotine dependence • This type of receptor is found in the ventral tegmental area (VTA) in the midbrain – the location of the cell bodies of the mesolimbic dopamine pathway binding site http://biology.ridley.on.ca/human_genome_project/hgi99/nicotineaddiction.htm http://www.cnsforum.com/content/pictures/imagebank/hirespng/rcpt_sys_nic_ag1.png

  6. The effect on the reward pathway • Stimulating the VTA nicotinic receptors results in dopamine release in the nucleus accumbens, but chronic stimulation by nicotine leads to reduced activity in the pathway in the absence of nicotine • Varenicline is thought to have enough activity reduce this deficiency without having sufficient activity to be rewarding itself • At the same time it blocks the receptor so that nicotine cannot get access to it, thus reducing the rewarding effects of nicotine

  7. Maximum effect Full agonist 100% Blocks reward Partial agonist Effect 50% Craving; Withdrawal relief 0% Dose, exposure Varenicline as a partial agonist 1. EMEA Package Insert. Annex I Summary of Product Characteristics. Pfizer Inc, New York, NY. 2006.

  8. Clinical findings • A 12-week course of varenicline 1mg bid. has been found to be safe and effective in large scale clinical trials • It appears to be more effective than the standard course of bupropion • Giving those who are abstinent at the end of the course a further 12 weeks of medication enhances long-term abstinence still further on average

  9. Treatment Period • Nontreatment Follow-up B W W W W W W W W W W W WL 1 2 3 4 5 6 7 8 9 10 11 12 W W W W W W W W W W W13 16 20 24 28 32 36 40 44 48 52 C C C C C C C C C C C C C C T T C T T C T C T C Comparative studies: design Treatment Phase Non-treatment Phase Varenicline 1 mg bid* Bupropion 150 mg bid* Placebo ScreeningVisit BaselineRandomization Week 12 Week 52 Randomization Target Quit Date *Titrated during Week 1. BL=baseline; W=week; C=clinic visit; T=telephone contact. 1. Jorenby DE, et al. JAMA. 2006;296:56-63. 2. Gonzales D, et al. JAMA. 2006;296:47-55.

  10. Odds Ratio (95% CI) V vs P 2.82 (2.06, 3.86; P<0.0001) V vs B 1.56 (1.19, 2.06; P<0.0013) B vs P 1.80 (1.29, 2.51; P<0.0004) 50 VareniclineBupropionPlacebo 45 40 35 30 25 20 15 10 5 0 Comparative studies: abstinence data 40 30 22.5% Responders(%) CA rate (%) 20 15.7% 9.4% 10 0 Varenicline 1 mg bid(n=692) Bupropion150 mg bid(n=669) Placebo(n=684) 12 16 20 24 28 32 36 40 44 48 52 Week Gonzales DH, Rennard SI, Billing CB, et al. A pooled analysis of varenicline: an α4β2 nicotinic receptor partial agonist vs. bupropion for smoking cessation. SRNT Paper sessions PA9-2, PA9-3, 2006.

  11. Comparative studies: recruitment to abstinence 1 • Some evidence that in the first 4 weeks, smokers on varenicline are being ‘recruited into abstinence’ – i.e. had smoked after the quit date but then became abstinence 2 1. Jorenby DE, et al. JAMA. 2006;296:56-63. 2. Gonzales D, et al. JAMA. 2006;296:47-55.

  12. Comparative studies: PROs • Analysis of the PROs (Patient-Reported Outcomes) indicates that varenicline: • reduced patient ratings of urges to smoke compared with placebo and bupropion • reduced ratings of mood disturbance compared with placebo • reduced patient ratings of satisfaction and reward from their cigarette in those who smoked a cigarette after the quit date, compared with placebo and bupropion Manuscript in preparation

  13. Open-label Treatment Double-blind Treatment Non-treatment Follow-up(Double-blind) B W W W W W W W W W WL 1 2 3 4 5 6 7 8 10 12 W W W W W13 14 16 20 24 W W W W W W W W W25 26 28 32 36 40 44 48 52 C C C C C C C C C C C C C C C C C T C T C T C T C Extended use study: design Open-labelPhase Double-blindPhase Non-treatmentFollow-up Phase Varenicline 1 mg bid Varenicline 1 mg bid(titrated) Placebo Baseline Week 12 Week 24 Week 52 Target Quit Date Randomization BL= baseline; W=week; C=clinic visit; T=telephone contact. 1.Tonstad S, et al. JAMA. 2006;296:64-71.

  14. Extended use study: findings Varenicline: 43.6% Placebo: 36.9% P=0.02 OR 1.34 % of Patients Week Tonstad S, et al. JAMA. 2006;296:64-71.

  15. Summary of safety data • During clinical trials, approximately 4000 individuals have been exposed to varenicline • In placebo-controlled studies, discontinuations due to adverse events were • 11.4% Varenicline 1 mg • 9.7% placebo • The most frequent (>10%) AEs associated with varenicline 1 mg vs placebo were • Nausea (28.6%) • Abnormal Dreams • Insomnia • Headache EMEA Package Insert. Annex I Summary of Product Characteristics. Pfizer Inc, New York, NY. 2006.

  16. Comparison with other medications • Direct comparison with bupropion has indicated an advantage for varenicline • No published studies comparing varenicline with nicotine replacement therapy but one study has been completed • Serious adverse event profile is favourable compared with bupropion but experience is much more limited

  17. Summary • Studies conducted to date have found varenicline to be safe and effective at helping smokers to stop. • The size of effect on abstinence appears to be greater than is found with a standard course of bupropion. • No serious adverse effects have been found but nausea is a relatively common side effect. • Adding a further 12 weeks to the initial course of 12 weeks of varenicline has been found in one study to improve abstinence rates 6 months after the end of treatment • Varenicline appears to work through two mechanisms: 1) reducing the need to smoke and 2) reducing the rewarding effect of the cigarette if the patient lapses in the first few weeks after the quit date, thus reducing the risk of that lapse turning into a full relapse • Varenicline was designed specifically to achieve this mechanism of action by being a partial agonist binding with high affinity to the alpha4beta2 nicotinic acetylcholine receptor which is believed to be central to the addictive properties of nicotine.

More Related